company background image
GRIN

Grown Rogue International CNSX:GRIN Stock Report

Last Price

CA$0.09

Market Cap

CA$15.4m

7D

-14.3%

1Y

-55.0%

Updated

03 Jul, 2022

Data

Company Financials
GRIN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends0/6

GRIN Stock Overview

Grown Rogue International Inc., through its subsidiaries, engages in growing and selling cannabis products in the United States.

Grown Rogue International Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Grown Rogue International
Historical stock prices
Current Share PriceCA$0.09
52 Week HighCA$0.21
52 Week LowCA$0.065
Beta0.75
1 Month Change0%
3 Month Change20.00%
1 Year Change-55.00%
3 Year Change-57.14%
5 Year Changen/a
Change since IPO-68.97%

Recent News & Updates

Jun 01
Does Grown Rogue International (CSE:GRIN) Have A Healthy Balance Sheet?

Does Grown Rogue International (CSE:GRIN) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Shareholder Returns

GRINCA PharmaceuticalsCA Market
7D-14.3%-9.5%-0.8%
1Y-55.0%-73.1%-5.0%

Return vs Industry: GRIN exceeded the Canadian Pharmaceuticals industry which returned -73.1% over the past year.

Return vs Market: GRIN underperformed the Canadian Market which returned -5% over the past year.

Price Volatility

Is GRIN's price volatile compared to industry and market?
GRIN volatility
GRIN Average Weekly Movement17.8%
Pharmaceuticals Industry Average Movement12.3%
Market Average Movement10.1%
10% most volatile stocks in CA Market17.4%
10% least volatile stocks in CA Market4.4%

Stable Share Price: GRIN is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: GRIN's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

FoundedEmployeesCEOWebsite
n/an/aJ. Stricklerhttps://www.grownrogue.com

Grown Rogue International Inc., through its subsidiaries, engages in growing and selling cannabis products in the United States. It offers flower products, such as indicas, sativas, and hybrids; and edibles, vape cartridges, pre-rolls, or concentrates. The company sells its products through dispensaries.

Grown Rogue International Fundamentals Summary

How do Grown Rogue International's earnings and revenue compare to its market cap?
GRIN fundamental statistics
Market CapUS$11.89m
Earnings (TTM)US$550.22k
Revenue (TTM)US$15.22m

21.6x

P/E Ratio

0.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GRIN income statement (TTM)
RevenueUS$15.22m
Cost of RevenueUS$5.33m
Gross ProfitUS$9.89m
Other ExpensesUS$9.34m
EarningsUS$550.22k

Last Reported Earnings

Apr 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.0032
Gross Margin64.97%
Net Profit Margin3.61%
Debt/Equity Ratio39.2%

How did GRIN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is GRIN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GRIN?

Other financial metrics that can be useful for relative valuation.

GRIN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.1x
Enterprise Value/EBITDA4.3x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does GRIN's PE Ratio compare to its peers?

GRIN PE Ratio vs Peers
The above table shows the PE ratio for GRIN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average13.3x
AYUR Ayurcann Holdings
30.3x138.3%CA$12.1m
J Lotus Ventures
13.7xn/aCA$6.7m
CXXI C21 Investments
3xn/aCA$42.6m
YOUR YourWay Cannabis Brands
6xn/aCA$23.2m
GRIN Grown Rogue International
21.6xn/aCA$15.4m

Price-To-Earnings vs Peers: GRIN is expensive based on its Price-To-Earnings Ratio (21.6x) compared to the peer average (13.3x).


Price to Earnings Ratio vs Industry

How does GRIN's PE Ratio compare vs other companies in the North American Pharmaceuticals Industry?

Price-To-Earnings vs Industry: GRIN is expensive based on its Price-To-Earnings Ratio (21.6x) compared to the Canadian Pharmaceuticals industry average (11.5x)


Price to Earnings Ratio vs Fair Ratio

What is GRIN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GRIN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate GRIN's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of GRIN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GRIN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GRIN's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GRIN's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Grown Rogue International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


72.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Grown Rogue International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Grown Rogue International's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Grown Rogue International competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Grown Rogue International performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


29.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GRIN has a large one-off loss of $783.1K impacting its April 30 2022 financial results.

Growing Profit Margin: GRIN became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: GRIN has become profitable over the past 5 years, growing earnings by 29% per year.

Accelerating Growth: GRIN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: GRIN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (118.1%).


Return on Equity

High ROE: GRIN's Return on Equity (18.7%) is considered low.


Discover strong past performing companies

Financial Health

How is Grown Rogue International's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: GRIN's short term assets ($8.1M) exceed its short term liabilities ($5.5M).

Long Term Liabilities: GRIN's short term assets ($8.1M) exceed its long term liabilities ($3.3M).


Debt to Equity History and Analysis

Debt Level: GRIN's net debt to equity ratio (18.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if GRIN's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: GRIN's debt is well covered by operating cash flow (36.5%).

Interest Coverage: GRIN's interest payments on its debt are well covered by EBIT (3.7x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Grown Rogue International current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate GRIN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GRIN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GRIN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GRIN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GRIN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

J. Strickler (42 yo)

3.67yrs

Tenure

US$174,882

Compensation

Mr. J. Obie Strickler serves as President, Chief Executive Officer and Chairman at Grown Rogue International Inc. He Co-Founded Grown Rogue International Inc. He is the Director of Grown Rogue Internationa...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether J.'s total compensation is reasonable compared to companies of similar size in the Canadian market.

Compensation vs Earnings: J.'s compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: GRIN's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: GRIN's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: GRIN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.8%.


Top Shareholders

Company Information

Grown Rogue International Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Grown Rogue International Inc.
  • Ticker: GRIN
  • Exchange: CNSX
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$15.357m
  • Shares outstanding: 170.63m
  • Website: https://www.grownrogue.com

Location

  • Grown Rogue International Inc.
  • 550 Airport Road
  • Medford
  • Oregon
  • 97504
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/03 00:00
End of Day Share Price2022/06/30 00:00
Earnings2022/04/30
Annual Earnings2021/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.